SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets


Previous 10 Next 10 
From: richardred9/24/2012 10:47:18 AM
   of 6272
 
New risky buy today. PTIE-Pain Therapeutics. IMO a lot of the wind has already been taken out of its sails for an earlier non FDA approval. Based on the hopes Pfizer can get FDA approval of REMOXY within 6 months.

I owned this one before and sold after the deal with King Pharmaceuticals lifted the stock. Pfizer bought King and the those rights. IMO the pain market with a harder to abuse pain killer is something the FDA can only ignore for so long. Purdue Frederick Company's market share is there for the taking if approved.
Message 26881747

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (3161)9/24/2012 11:14:35 AM
From: richardred
   of 6272
 
LNDC-sold some more LNDC today. Just in case earnings disappoint.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (3164)9/25/2012 2:57:24 PM
From: richardred
   of 6272
 
KRA- Sold other half today on the spike today.

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (3123)9/26/2012 11:35:07 AM
From: richardred
   of 6272
 
Chemtura -made a bolt on today. I'll still hold ACET.
Chemtura to acquire bromine assets of Solaris ChemTech Industries Ltd.http://finance.yahoo.com/news/chemtura-acquire-bromine-assets-solaris-123322563.html

Share RecommendKeepReplyMark as Last Read


From: richardred9/27/2012 12:52:06 AM
   of 6272
 
New buy after I left for work- SKY- Skyline- Partial execution of GTC order.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred9/28/2012 11:16:17 AM
   of 6272
 
I think I'm done buying for awhile, but that can change due to market conditions. Recent sales have brought me to over 40% cash for now.

New buy today- Nibbled on some APFC- American Pacific Corp

I owned this one before in the distant past (highly volatile company).
IMO the company is in transition and timely. They sold some major aerospace operations for 46 mill to Moog Corp. A company I used to own. That sale should help the balance sheet out and help stabilize earnings. Moody's recently upgraded debt. I like the fact the company has a monopoly on sodium azide. They own American Azide Corporation Witch is the sole North American manufacturer of sodium azide, a chemical with uses as an intermediate in the pharmaceutical industry as well as other applications. The stock has run up but I think the company might be on the growth path. At 10 times forward earnings it doesn't seem overvalued. I also believe it has some good speculative appeal. It seems a good replacement for my CBM witch I sold out of.

Interesting kicker-AMPAC has intellectual property rights to the use of sodium azide as the active ingredient in SEP® 100, a proprietary formulation that functions as a safe broad-spectrum pesticide. It is an effective zero ozone depletion potential replacement for ozone-depleting methyl bromide as it performs well as a fungicide (controlling fungus), nematicide (controlling nematodes), herbicide (controlling weeds or other unwanted plants) and a bacteriacide (controlling unwanted bacteria in the soil). Its approval by the U.S. EPA and other regulatory bodies is pending.

finance.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: richardred who wrote (3174)9/29/2012 5:07:55 AM
From: ~digs
   of 6272
 
APFC nice trend keying off supportive 50ema

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (3099)9/29/2012 11:14:16 AM
From: richardred
   of 6272
 
No competing bids, but the money is in the bank finally.

Forestar Group completes Credo acquisition
Austin Business Journal by Sarah Drake, Web Editor Date: Friday, September 28, 2012, 11:24am CDT




Enlarge Image

File photo
The local company has completed its acquisition of Denver-based Credo Petroleum Corp.




Austin’s Forestar Group Inc. has completed its acquisition of a Denver oil and gas exploration, development and production company.

Forestar (NYSE: FOR) — which agreed in June to buy Credo Petroleum Corp. (Nasdaq: CRED) — will pay $146 million, company officials said in a news release.

Credo owns leasehold interests in more than 135,000 net mineral acres between North Dakota, Kansas, Nebraska and Texas.

Forestar, which was founded in 2006 as a division of Austin-based Temple-Inland Inc., is a real estate, mineral and fiber resources management firm. The company employs 101 workers.

In August, the local company reported a profit of $811,000 on $35.3 million in revenue during the second quarter, up from a loss of $3.9 million on $25.5 million in revenue during the same three months last year.

bizjournals.com

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (2601)10/1/2012 11:00:29 AM
From: richardred
   of 6272
 
Two companies I watch that have takeovers in their business growth strategies are buying today.

3M, Honeywell set takeovers to expand product lines.

(Reuters) - 3M Co and Honeywell International Inc signed separate takeover deals to expand their broad lineups of industrial goods at a time of uncertainty for the U.S. economy, the top U.S. manufacturers said on Monday.

3M said it would pay $860 million to buy industrial ceramics company Ceradyne Inc. This is the biggest takeover deal for the maker of products ranging from Post-It notes to films used in television screens since it named Inge Thulin chief executive officer in February.

Honeywell announced plans to pay $525 million in cash for a 70 percent stake in privately held Thomas Russell Co, which makes equipment used in natural gas production. Big U.S. manufacturers including General Electric Co have invested heavily to boost their exposure to that sector amid a surge in U.S. natural gas production driven by advances in hydraulic fracturing, or fracking, technology.

The announcements come less than two weeks after the CEOs of both Honeywell and 3M separately said that a worrisome world economic outlook was making it easier to negotiate acquisitions by tempering expectations of what companies would fetch.

"If the asset makes sense and the price makes sense, you go for it," said independent analyst Brian Langenberg.

Ceradyne shares were up 43 percent at $34.94 in early trading, just below the $35.00 offer price from 3M, whose stock gained 1 percent to $93.32. Honeywell rose 1.7 percent to $60.74.

FEWER, BUT LARGER 3M DEALS

Thulin told investors on September 19 that he would seek fewer, but larger, deals than his predecessor, George Buckley, but he held to the company's long-term goal of making $1 billion to $2 billion in acquisitions per year.

The company has yet another large deal in the works - it is working to overcome U.S. regulators' objections to its planned $550 million takeover of Avery-Dennison Corp's office products business.

Meanwhile, Honeywell's UOP arm has the right to buy the remaining 30 percent of Thomas Russell, at a price linked to the business's operating income.

The decade-old Thomas Russell company should generate 2012 revenue of about $425 million, Honeywell said.

Honeywell said it expected its deal to have no effect on 2012 profit and to boost 2013 earnings.

3M said its deal would reduce earnings by 5 cents per share in the first months following closure.

(Reporting by Scott Malone in Boston; Editing by Lisa Von Ahn)

finance.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (3)


To: richardred who wrote (3091)10/5/2012 11:12:38 AM
From: richardred
   of 6272
 
Incoming Avon Chairman No Stranger to DealsBy Mia Lamar
Asociated PressAndrea Jung
Avon Chairman Andrea Jung will be passing the reins to a well-known private-equity executive, a potentially good sign for investors still hoping for a deal.

Avon announced today that Jung, who had already relinquished the chief executive spot at the beauty-products company, will step down at year end. Fred Hassan, a currently lead independent director and a partner at Warburg Pincus, will succeed her.

Hassan has made a name for himself as a turnaround expert and three years ago led Schering-Plough to sell to Merck when he was CEO of the drugmaker.

Earlier this year Avon disappointed investors when it refused to to sell perfume maker Coty for $10.7 billiond.

The question now: Will Hassan now turn to prettying up Avon for a sale?

Shares of Avon are down nearly 25% since Coty withdrew its $24.75 a share bid in May, are up 5.5% premarket in recent trading.

blogs.wsj.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10